drugset / Trial / NCT01250717

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

NCT01250717

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine if the combination of chemotherapy and hormone therapy is safe and helpful for patients who plan to have their high-risk prostate cancer surgically removed. Some physicians believe that patients with high risk cancer that is located in one area, may have an early but small spread of the cancer outside of the prostate, and perhaps even to distant organs. Therefore, better treatments for the entire body are needed to improve the ability of surgery or other local therapies to cure prostate cancer. Since chemotherapy is beginning to demonstrate increasing activity in advanced prostate cancer patients, it is possible that using chemotherapy combined with hormonal therapy earlier in the course of localized but high risk patients might improve the outcomes for these patients.

Timeline

Start
2001-01
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bicalutamide Other / unclassified Oral
Subject Docetaxel Small molecule Intravenous
Subject Goserelin Other / unclassified Subcutaneous
Subject estramustine Other / unclassified Oral
Background Dexamethasone Small molecule Oral

Indications